WO2002052016A2 - Regulation of human protein l-isoaspartate o-methyltransferase-like enzyme - Google Patents
Regulation of human protein l-isoaspartate o-methyltransferase-like enzyme Download PDFInfo
- Publication number
- WO2002052016A2 WO2002052016A2 PCT/EP2001/015001 EP0115001W WO02052016A2 WO 2002052016 A2 WO2002052016 A2 WO 2002052016A2 EP 0115001 W EP0115001 W EP 0115001W WO 02052016 A2 WO02052016 A2 WO 02052016A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- isoaspartate
- enzyme
- protein
- seq
- Prior art date
Links
- 108090000790 Enzymes Proteins 0.000 title claims abstract 44
- 102000004190 Enzymes Human genes 0.000 title claims abstract 43
- 102000003839 Human Proteins Human genes 0.000 title claims abstract 12
- 108090000144 Human Proteins Proteins 0.000 title claims abstract 12
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract 24
- 201000010099 disease Diseases 0.000 claims abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract 3
- 201000011510 cancer Diseases 0.000 claims abstract 3
- 230000004064 dysfunction Effects 0.000 claims abstract 2
- 229920001184 polypeptide Polymers 0.000 claims 51
- 238000000034 method Methods 0.000 claims 49
- 102000004196 processed proteins & peptides Human genes 0.000 claims 49
- 108090000765 processed proteins & peptides Proteins 0.000 claims 49
- 108091033319 polynucleotide Proteins 0.000 claims 30
- 102000040430 polynucleotide Human genes 0.000 claims 30
- 239000002157 polynucleotide Substances 0.000 claims 30
- 102000004169 proteins and genes Human genes 0.000 claims 30
- 108090000623 proteins and genes Proteins 0.000 claims 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims 25
- 230000000694 effects Effects 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 21
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 13
- 239000013604 expression vector Substances 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000012472 biological sample Substances 0.000 claims 6
- 238000012216 screening Methods 0.000 claims 6
- 238000009396 hybridization Methods 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 230000007423 decrease Effects 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000000463 material Substances 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 229940124606 potential therapeutic agent Drugs 0.000 claims 4
- 239000002299 complementary DNA Substances 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 210000004671 cell-free system Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 230000001603 reducing effect Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Abstract
Reagents that regulate human protein L-isoaspartate O-methyltransferase-like enzyme and reagents which bind to human protein L-isoaspartate O-methyltransferase-like enzyme gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer.
Claims
1. An isolated polynucleotide being selected from the group consisting of:
a) a polynucleotide encoding a protein L-isoaspartate O-methylfransferase- like enzyme polypeptide comprising an amino acid sequence selected form the group consisting of:
amino acid sequences which are at least about 88% identical to the amino acid sequence shown in SEQ ID NO: 2; and the amino acid sequence shown in SEQ ID NO: 2.
b) a polynucleotide comprising the sequence of SEQ ID NO: 1 ;
c) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) and (b) and encodes a protein L- isoaspartate O-methylfransferase-like enzyme polypeptide;
d) a polynucleotide the sequence of which deviates from the poly- nucleotide sequences specified in (a) to (c) due to the degeneration of the genetic code and encodes a protein L-isoaspartate O- methylfransferase-like enzyme polypeptide; and
e) a polynucleotide which represents a fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d) and encodes a protein L-isoaspartate O-methylfransferase-like enzyme polypeptide.
2. An expression vector containing any polynucleotide of claim 1.
3. A host cell containing the expression vector of claim 2.
76 -
4. A substantially purified protein L-isoaspartate O-methyltransferase-like enzyme polypeptide encoded by a polynucleotide of claim 1.
5. A method for producing a protem L-isoaspartate O-methylfransferase-like enzyme polypeptide, wherein the method comprises the following steps:
a) culturing the host cell of claim 3 under conditions suitable for the expression of the protein L-isoaspartate O-methylfransferase-like enzyme polypeptide; and
b) recovering the protein L-isoaspartate O-methyltransferase-like enzyme polypeptide from the host cell culture.
6. A method for detection of a polynucleotide encoding a protein L-isoaspartate
O-methylfransferase-like enzyme polypeptide in a biological sample comprising the following steps:
a) hybridizing any polynucleotide of claim 1 to a nucleic acid material of a biological sample, thereby forming a hybridization complex; and
b) detecting said hybridization complex.
7. The method of claim 6, wherein before hybridization, the nucleic acid material of the biological sample is amplified.
8. A method for the detection of a polynucleotide of claim 1 or a protein L- isoaspartate O-methylfransferase-like enzyme polypeptide of claim 4 comprising the steps of:
- 77 -
contacting a biological sample with a reagent which specifically interacts with the polynucleotide or the protein L-isoaspartate O-methylfransferase-like enzyme polypeptide.
9. A diagnostic kit for conducting the method of any one of claims 6 to 8.
10. A method of screening for agents which decrease the activity of a protein L- isoaspartate O-methyltransferase-like enzyme, comprising the steps of:
contacting a test compound with any protein L-isoaspartate O-methylfransferase-like enzyme polypeptide encoded by any polynucleotide of clai ! ;
detecting binding of the test compound to the protein L-isoaspartate O- methyltransferase-like enzyme polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential therapeutic agent for decreasing the activity of a protein L-isoaspartate O-methyltransferase-like enzyme.
11. A method of screening for agents which regulate the activity of a protein L- isoaspartate O-methylfransferase-like enzyme, comprising the steps of:
contacting a test compound with a protein L-isoaspartate O-methyltransferase-like enzyme polypeptide encoded by any polynucleotide of claim 1; and
detecting a protein L-isoaspartate O-methyltransferase-like enzyme activity of the polypeptide, wherein a test compound which increases the protein L- isoaspartate O-methylfransferase-like enzyme activity is identified as a potential therapeutic agent for increasing the activity of the protein L- isoaspartate O-methyltransferase-like enzyme, and wherein a test compound which decreases the protein L-isoaspartate O-methylfransferase-like enzyme activity of the polypeptide is identified as a potential therapeutic agent for
78 -
decreasing the activity of the protein L-isoaspartate O-methyltransferase-like enzyme.
12. A method of screening for agents which decrease the activity of a protein L- isoaspartate O-methyltransferase-like enzyme, comprising the steps of:
contacting a test compound with any polynucleotide of claim 1 and detecting binding of the test compound to the polynucleotide, wherein a test compound which binds to the polynucleotide is identified as a potential therapeutic agent for decreasing the activity of protein L-isoaspartate O-methylfransferase-like enzyme.
13. A method of reducing the activity of protein L-isoaspartate O-methyltransferase- like enzyme, comprising the steps of:
contacting a cell with a reagent which specifically binds to any polynucleotide of claim 1 or any protein L-isoaspartate O-methyltransferase-like enzyme polypeptide of claim 4, whereby the activity of protein L-isoaspartate O- methyltransferase-like enzyme is reduced.
14. A reagent that modulates the activity of a protein L-isoaspartate O- methyltransferase-like enzyme polypeptide or a polynucleotide wherein said reagent is identified by the method of any of the claim 10 to 12.
15. A pharmaceutical composition, comprising: the expression vector of claim 2 or the reagent of claim 14 and a pharmaceutically acceptable carrier.
16. Use of the expression vector of claim 2 or the reagent of claim 14 in the preparation of a medicament for modulating the activity of a protein L- isoaspartate O-methyltransferase-like enzyme in a disease.
79 -
17. Use of claim 16 wherem the disease is cancer.
18. A cDNA encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2.
19. The cDNA of claim 18 which comprises SEQ ID NO: 1.
20. The cDNA of claim 18 which consists of SEQ ID NO: 1.
21. An expression vector comprising a polynucleotide which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2.
22. The expression vector of claim 21 wherein the polynucleotide consists of SEQ JJD NO: l.
23. A host cell comprising an expression vector which encodes a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2.
24. The host cell of claim 23 wherein the polynucleotide consists of SEQ ID NO:
1.
25. A purified polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2.
26. The purified polypeptide of claim 25 which consists of the amino acid sequence shown in SEQ ID NO: 2.
27. A fusion protein comprising a polypeptide having the amino acid sequence shown in SEQ ID NO: 2.
80
28. A method of producing a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2, comprising the steps of:
culturing a host cell comprising an expression vector which encodes the polypeptide under conditions whereby the polypeptide is expressed; and
isolating the polypeptide.
29. The method of claim 28 wherein the expression vector comprises SEQ ID NO: 1.
30. A method of detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2, comprising the steps of:
hybridizing a polynucleotide comprising 11 contiguous nucleotides of SEQ
ID NO: 1 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and
detecting the hybridization complex.
31. The method of claim 30 further comprising the step of amplifying the nucleic acid material before the step of hybridizing.
32. A kit for detecting a coding sequence for a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2, comprising:
a polynucleotide comprising 11 contiguous nucleotides of SEQ ID NO: 1; and instructions for the method of claim 30.
33. A method of detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2, comprising the steps of:
81
contacting a biological sample with a reagent that specifically binds to the polypeptide to form a reagent-polypeptide complex; and
detecting the reagent-polypeptide complex.
34. The method of claim 33 wherein the reagent is an antibody.
35. A kit for detecting a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2, comprising:
an antibody which specifically binds to the polypeptide; and
instructions for the method of claim 33.
36. A method of screening for agents which can modulate the activity of a human protein L-isoaspartate O-methylfransferase-like enzyme, comprising the steps of:
contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of: (1) amino acid sequences which are at least about 88% identical to the amino acid sequence shown in SEQ ID NO: 2 and (2) the amino acid sequence shown in SEQ ID NO: 2; and
detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential agent for regulating activity of the human protein L-isoaspartate O-methyltransferase- like enzyme.
37. The method of claim 36 wherein the step of contacting is in a cell.
- 82 -
38. The method of claim 36 wherein the cell is in vitro.
39. The method of claim 36 wherein the step of contacting is in a cell-free system.
40. The method of claim 36 wherein the polypeptide comprises a detectable label.
41. The method of claim 36 wherem the test compound comprises a detectable label.
42. The method of claim 36 wherein the test compound displaces a labeled ligand which is bound to the polypeptide.
43. The method of claim 36 wherein the polypeptide is bound to a solid support.
44. The method of claim 36 wherein the test compound is bound to a solid support.
45. A method of screening for agents which modulate an activity of a human protem L-isoaspartate O-methylfransferase-like enzyme, comprising the steps of:
contacting a test compound with a polypeptide comprising an amino acid sequence selected from the group consisting of: (1) amino acid sequences which are at least about 88% identical to the amino acid sequence shown in
SEQ TJD NO: 2 and (2) the amino acid sequence shown in SEQ ID NO: 2; and
detecting an activity of the polypeptide, wherein a test compound which increases the activity of the polypeptide is identified as a potential agent for increasing the activity of the human protein L-isoaspartate O-methyltransferase- like enzyme, and wherein a test compound which decreases the activity of the
- 83 -
polypeptide is identified as a potential agent for decreasing the activity of the human protein L-isoaspartate O-methylfransferase-like enzyme.
46. The method of claim 45 wherein the step of contacting is in a cell.
47. The method of claim 45 wherein the cell is in vitro.
48. The method of claim 45 wherein the step of contacting is in a cell-free system.
49. A method of screening for agents which modulate an activity of a human protein L-isoaspartate O-methylfransferase-like enzyme, comprising the steps of:
contacting a test compound with a product encoded by a polynucleotide which comprises the nucleotide sequence shown in SEQ ID NO: 1; and
detecting binding of the test compound to the product, wherein a test compound which binds to the product is identified as a potential agent for regulating the activity of the human protein L-isoaspartate O-methyltransferase-like enzyme.
50. The method of claim 49 wherein the product is a polypeptide.
51. The method of claim 49 wherein the product is RNA.
52. A method of reducing activity of a human protein L-isoaspartate O- methyltransferase-like enzyme, comprising the step of:
contacting a cell with a reagent which specifically binds to a product encoded by a polynucleotide comprising the nucleotide sequence shown in SEQ ID
- 84 -
NO: 1, whereby the activity of a human protein L-isoaspartate O- methyltransferase-like enzyme is reduced.
53. The method of claim 52 wherein the product is a polypeptide.
54. The method of claim 53 wherein the reagent is an antibody.
55. The method of claim 52 wherein the product is RNA.
56. The method of claim 55 wherein the reagent is an antisense oligonucleotide.
57. The method of claim 56 wherein the reagent is a ribozyme.
58. The method of claim 52 wherein the cell is in vitro.
59. The method of claim 52 wherein the cell is in vivo.
60. A pharmaceutical composition, comprising:
a reagent which specifically binds to a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2; and
a pharmaceutically acceptable carrier.
61. The pharmaceutical composition of claim 60 wherein the reagent is an antibody.
62. A pharmaceutical composition, comprising:
a reagent which specifically binds to a product of a polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 1; and
85
a pharmaceutically acceptable carrier.
63. The pharmaceutical composition of claim 62 wherein the reagent is a ribozyme.
64. The pharmaceutical composition of claim 62 wherein the reagent is an antisense oligonucleotide.
65. The pharmaceutical composition of claim 62 wherein the reagent is an antibody.
66. A pharmaceutical composition, comprising:
an expression vector encoding a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2; and
a pharmaceutically acceptable carrier.
67. The pharmaceutical composition of claim 66 wherein the expression vector comprises SEQ ID NO: 1.
68. A method of treating a protein L-isoaspartate O-methylfransferase-like enzyme dysfunction related disease, wherein the disease is cancer comprising the step of:
administering to a patient in need thereof a therapeutically effective dose of a reagent that modulates a function of a human protein L-isoaspartate O- methylfransferase-like enzyme, whereby symptoms of the protein L- isoaspartate O-methylfransferase-like enzyme disfunction related disease are ameliorated.
- 86
69. The method of claim 68 wherein the reagent is identified by the method of claim 36.
70. The method of claim 68 wherein the reagent is identified by the method of claim 45.
71. The method of claim 68 wherein the reagent is identified by the method of claim 49.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002217134A AU2002217134A1 (en) | 2000-12-26 | 2001-12-19 | Regulation of human protein l-isoaspartate o-methyltransferase-like enzyme |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25729200P | 2000-12-26 | 2000-12-26 | |
| US60/257,292 | 2000-12-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002052016A2 true WO2002052016A2 (en) | 2002-07-04 |
| WO2002052016A3 WO2002052016A3 (en) | 2002-11-07 |
Family
ID=22975669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2001/015001 WO2002052016A2 (en) | 2000-12-26 | 2001-12-19 | Regulation of human protein l-isoaspartate o-methyltransferase-like enzyme |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002217134A1 (en) |
| WO (1) | WO2002052016A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057204A2 (en) * | 2002-01-08 | 2003-07-17 | Nordic Bioscience A/S | Modulation of iamt (pimt or pcmt) in immune system |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996012797A1 (en) * | 1994-10-19 | 1996-05-02 | The Regents Of The University Of California | Production and use of human and plant methyltransferases |
| WO1998015647A1 (en) * | 1996-10-08 | 1998-04-16 | Novartis Ag | Modulation of apoptosis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1074617A3 (en) * | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
| EP1328636A2 (en) * | 2000-09-01 | 2003-07-23 | Nuvelo Inc. | Nucleic acids and polypeptides |
-
2001
- 2001-12-19 AU AU2002217134A patent/AU2002217134A1/en not_active Abandoned
- 2001-12-19 WO PCT/EP2001/015001 patent/WO2002052016A2/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996012797A1 (en) * | 1994-10-19 | 1996-05-02 | The Regents Of The University Of California | Production and use of human and plant methyltransferases |
| WO1998015647A1 (en) * | 1996-10-08 | 1998-04-16 | Novartis Ag | Modulation of apoptosis |
Non-Patent Citations (5)
| Title |
|---|
| ASWAD D W ET AL: "ISOASPARTATE IN PEPTIDES AND PROTEINS: FORMATION, SIGNIFICANCE, AND ANALYSIS" JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, NEW YORK, NY, US, vol. 21, 2000, pages 1129-1138, XP002902282 ISSN: 0731-7085 * |
| DATABASE EMBL [Online] Standard; DNA; HUM; 3699 BP , TANG Y. ET AL.: "Sequence 124 from Patent WO0218424" Database accession no. AX399953 XP002208538 -& WO 02 18424 A (HYSEQ INC. (US)) 7 March 2002 (2002-03-07) * |
| DATABASE EMBL [Online] standard; Protein; 361 AA, OTA T. ET AL.: "Human protein sequence Seq ID No:12350 " Database accession no. AAB93292 XP002208536 -& EP 1 074 617 A ((HELI-) HELIX RES INST.) 7 February 2001 (2001-02-07) * |
| DATABASE EMBL [Online] standard; RNA; HUM; 3655 BP, 22 February 2000 (2000-02-22) ISOGAI T. ET AL.: "Homo sapiens cDNA FLJ10883 fis, clone NT2RP4001946, weakly similar to PROTEIN-L-ISOASPARTASE O-METHYLTRANSFERASE (EC 2.1.1.77)" Database accession no. AK001745 XP002208535 * |
| DATABASE EMBL [Online] standard;cDNA; 3655 BP, OTA T. ET AL.: "Human cDNA sequence Seq ID No 12349" Database accession no. AAH14668 XP002208537 -& EP 1 074 617 A ((HELI-) HELIX RES INST) 7 February 2001 (2001-02-07) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003057204A2 (en) * | 2002-01-08 | 2003-07-17 | Nordic Bioscience A/S | Modulation of iamt (pimt or pcmt) in immune system |
| WO2003057204A3 (en) * | 2002-01-08 | 2004-02-05 | Nordic Bioscience As | Modulation of iamt (pimt or pcmt) in immune system |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002217134A1 (en) | 2002-07-08 |
| WO2002052016A3 (en) | 2002-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hoshino et al. | A human homologue of the yeast GST1 gene codes for a GTP‐binding protein and is expressed in a proliferation‐dependent manner in mammalian cells. | |
| O'brien et al. | Expression of cyr61, a growth factor-inducible immediate-early gene | |
| CA2147499A1 (en) | Prostate-specific membrane antigen | |
| EP0020147B1 (en) | A dna transfer vector for human pre-growth hormone, a microorganism transformed thereby, and a method of cloning therefor | |
| JP2002508970A5 (en) | ||
| AU2008267138B2 (en) | FSH producing cell clone | |
| CA2181431A1 (en) | Haemopoietic maturation factor | |
| CA2589951A1 (en) | Method for producing carboxy-terminal amidated peptides | |
| DE69530944T2 (en) | KERATINOCYTE GROWTH FACTOR 2 | |
| CA2418422A1 (en) | Novel kallikrein gene | |
| US20020160451A1 (en) | Novel orphan receptors | |
| JPH0193537A (en) | Inhibitor of angiogenine | |
| CA2195090A1 (en) | Lkp pilin structural genes and operon of nontypable haemophilus influenzae | |
| WO1992011290A1 (en) | Medicaments for the treatment of papillomavirus diseases | |
| JPH09511140A (en) | Stanniocalcin, a protein in the body of Stannius | |
| CA2183253A1 (en) | Rna editing enzyme and methods of use thereof | |
| EP0291686B1 (en) | Inhibitors of angiogenin | |
| WO2002052016A2 (en) | Regulation of human protein l-isoaspartate o-methyltransferase-like enzyme | |
| WO1991012272A1 (en) | Protein factor | |
| JP2004533848A5 (en) | ||
| JPH10500019A (en) | Human oxalyl-CoA decarboxylase | |
| CN106496330B (en) | A kind of VDR-His fusion proteins and its DNA sequence dna, expression and application | |
| US8278414B2 (en) | DNA sequence encoding a retinoic acid regulated protein | |
| AU753400B2 (en) | Orphan receptors | |
| CA2418848A1 (en) | Cng2b: a novel human cyclic nucleotide-gated ion channel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |